Bap1 Tumor Predisposition Syndrome
📧 Sign up to get email alerts when something new happens for Bap1 Tumor Predisposition Syndrome.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-04-17Clinical Trial Update: Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma [Phase 2]
A Phase 2 trial of INQOVI (decitabine/cedazuridine) in patients with BAP1 tumor predisposition syndrome and subclinical, early-stage mesothe…